TITLE

Adverse effect of additional weight on exercise against gravity in patients with chronic obstructive airways disease

AUTHOR(S)
Swinburn, C R; Cooper, B G; Mould, H; Corris, P A; Gibson, G J
PUB. DATE
September 1989
SOURCE
Thorax;Sep1989, Vol. 44 Issue 9, p716
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66029041

 

Related Articles

  • Oxygen as a driving gas for nebulisers: safe or dangerous? Gunawardena, K.A.; Patel, B.; Campbell, I.A.; MacDonald, J.B.; Smith, A.P. // British Medical Journal (Clinical Research Edition);1/28/1984, Vol. 288 Issue 6413, p272 

    Examines the effectiveness of oxygen as a driving gas for nebulisers. Types of patients with airways obstruction; Use of nebulized bronchodilators in the management of severe asthma; Details on the exacerbations of chronic obstructive airways disease.

  • ABC of chronic obstructive pulmonary disease. Currie, Graeme P.; Lipworth, Brian J. // BMJ: British Medical Journal (International Edition);6/17/2006, Vol. 332 Issue 7555, p1439 

    The article presents information on inhaled treatment for patients with chronic obstructive airways disease (COPD). According to the article, all patients with COPD should be prescribed a short acting bronchodilator. The article discusses long acting bronchodilators, inhaled corticosteroids,...

  • Upper Extremity Exercise in Rehabilitation of COPD. Celli, Bartolome R. // Clinical & Investigative Medicine;Jun2001 Supplement, Vol. 24, pS37 

    The article discusses the upper extremity exercise in rehabilitation of chronic obstructive pulmonary disease (COPD). Humans use their arms to perform activities of daily living, to work and to recreate themselves. Some of the muscles of the shoulder girdle have a dual function; to help breathe...

  • pirbuterol.  // Davis's Drug Guide for Nurses, 9th edition;2005, p856 

    Provides information on the bronchodilator and adrenergic agent pirbuterol. Use of the drug for the management of reversible airway disease due to asthma or chronic obstructive pulmonary disease; Actions and adverse side effects of the drug; Administration of the drug.

  • Roflumilast: A Review in COPD. Garnock-Jones, Karly // Drugs;Sep2015, Vol. 75 Issue 14, p1645 

    Roflumilast (Daliresp, Daxas) is a selective phosphodiesterase 4 (PDE4) inhibitor that decreases systemic and pulmonary inflammation and improves disease symptoms in patients with severe chronic obstructive pulmonary disease (COPD). This article reviews the pharmacological properties of...

  • Kronik Obstr�ktif Akciger Hastaliginin Sistemik Etkileri. BOZBAs, serife SAVAs; ULUBAY, Gaye // Akciger Arsivi/Archives of Lung;2010, Vol. 11 Issue 2, p47 

    Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation in the lungs. Chronic obstruction to airflow is seen due to structural changes in lung parenchyma and airways. These structural changes observed in COPD are related to inflammation in the airways, alveoli and...

  • Controlled trial supervised exercise training in chronic bronchitis. Sinclair, D.J.M.; Ingram, C.G. // British Medical Journal;2/23/1980, Vol. 280 Issue 6213, p519 

    Examines the effectiveness of supervised exercise training for chronic bronchitis patients. Improvement in walking distance of patients; Changes in the cardiorespiratory function; Benefits of exercise rehabilitation for patients with obstructive lung disease.

  • Relation of birth weight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. Barker, D.J.P.; Godfrey, K.M.; Fall, C.; Osmond, C.; Winter, P.D.; Shaheen, S.O. // BMJ: British Medical Journal (International Edition);9/21/91, Vol. 303 Issue 6804, p671 

    Assesses the association of birth weight, infant weight and childhood respiratory infection with adult lung function and death caused by chronic obstructive airways disease. Effect of low birth weight on adult lung function; Impact of lung disease in infancy on weight gain; Importance of...

  • Umeclidinium-vilanterol: First once-daily dual bronchodilator for COPD. YOUNG, CARA ALDRIDGE // Pharmacy Today;Feb2014, Vol. 20 Issue 2, p28 

    The article reports on the approval for umeclidinium-vilanterol powder by the U.S. Food & Drug Administration as a dual bronchodilator for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). The contraindications of the use of the drug in patients with asthma are...

  • albuterol.  // Davis's Drug Guide for Nurses, 10th edition;2007, p97 

    The article presents a nursing guide for the bronchodilator albuterol. The drug is used for the control and prevention of reversible airway obstruction caused by asthma or chronic obstructive pulmonary disease (COPD). It explains the pharmacokinetics, contraindications, precautions, adverse...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics